Recent Updates
Recently added Catalysts
INO Positive Sentiment

INOVIO to Participate in Upcoming Scientific Conferences

Friday, May 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: INOVIO (NASDAQ:INO) has announced its participation in two prominent scientific conferences, the American Society of Gene and Cell Therapy Annual Meeting in Boston and the American Society of Clinical Oncology Annual Meeting in Chicago. At these events, the company will present research related to gene treatments for hemophilia A and DNA immunotherapy for Recurrent Respiratory Papillomatosis. Following the presentations, abstracts will be made available on INOVIO's website to share further details of the research.
Price reaction · baseline $1.37 (2026-05-07 close) · hit after-hours · 1 other INO headline(s) in the window, move may be shared
day 0 close · peak
+6.6%
day 1
+4.4%
day 3
-2.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • INOVIO is advancing its presence in the scientific community by participating in significant conferences.
  • The company is showcasing innovative research in gene therapy and immunotherapy.
  • Presentations at major industry meetings can enhance INOVIO's visibility and credibility.
  • Available abstracts post-presentation will provide additional insights into their research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
High dilution risk
Lead asset
VGX-410
Phase 2 · Hepatitis C Virus Infection

Full Press Release Details

PLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences:
American Society of Gene and Cell Therapy Annual Meeting (Boston)
Poster Presentation: Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells
Date: Tuesday, May 12
Time: 5 - 6:30 PM ET
American Society of Clinical Oncology Annual Meeting (Chicago)
Poster Presentation: B cell responses in Recurrent Respiratory Papillomatosis patients treated with DNA immunotherapy INO-3107
Date: Saturday, May 30
Time: 1:30 - 4:30 PM CDT
Available abstracts will be shared on INOVIO's website following presentations.
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Frequently Asked Questions

What is INOVIO's focus in biotechnology?

INOVIO specializes in developing DNA medicines for HPV-related diseases, cancer, and infections.

When is INOVIO presenting at the American Society of Gene and Cell Therapy?

INOVIO will present on May 12, from 5 - 6:30 PM ET in Boston.

What topic will be discussed at the ASCO Annual Meeting?

The presentation will cover B cell responses in Recurrent Respiratory Papillomatosis patients treated with INO-3107.

Where can I find INOVIO's presentation abstracts?

Abstracts will be available on INOVIO's website after the presentations.

How can I contact INOVIO's media relations?

You can contact media relations through Jennie Willson at (267) 429-8567.

ShareAdd on Google
Tags: INO Viatris Investor Conferences Healthcare INOVIO DNA medicines scientific conferences hemophilia A immunotherapy
Last updated: May 8, 2026

Biotech snapshot

Cash runway
$37M liquidity · $6M/mo burn
~6 mo
High dilution risk
Lead asset
VGX-410Phase 2
Hepatitis C Virus Infection →